In addition drugs as Ibrutinib [23] (DScore 0.822) and Acalabrutinib (DScore 0.812) Burton’s tyrosine-kinase inhibitors used in chronic lymphoid leukemia and mantle-cell lymphoma shows activity against JAK3 [34], which is mutated in our patient. The gene discussed is JAK3; the disease is mantle cell lymphoma.